ASSESSMENT OF WILMS TUMOR GENE (WT1) IN ACUTE MYELOID LEUKEMIA PATIENTS AS A NEW MARKER TO DETECT MINIMAL RESIDUAL DISEASE (MRD)

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

HEMMATI T.; GHAFARI H.; ALI MOGHADAM K.; GHARAH BAGHIAN A.; ROSTAMI SH.; ASHOORI A.

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: The Scientific Journal of Iranian Blood Transfusion Year:2006 | Volume:3 | Issue:3 Page(s): 233-241

Download Full-Text

Persian Verion

View:

1,867

Download:

Cites:

Information Journal Paper

Title

ASSESSMENT OF WILMS TUMOR GENE (WT1) IN ACUTE MYELOID LEUKEMIA PATIENTS AS A NEW MARKER TO DETECT MINIMAL RESIDUAL DISEASE (MRD)

Author(s)

Keywords

WT1 GENEQ4

MINIMAL RESIDUAL DISEASE (MRD)Q4

PCRQ4

Abstract

Background and Objectives: WT1 GENE encodes a transcription factor that is involved in differentiation and proliferation of hematopoietic precursor cells as well as some other tissues like kidney, ovary, heart, etc. Quantitative assessment of WT1 GENE expression is proposed as a useful marker in MRD detection and leukemia management. Materials and Methods: To assess the relevance of this gene, we analysed peripheral blood mononuclear cells of 62 AML patients (new cases) for the expression level of WT1 mRNA using Real-time quantitative RT-PCR. We followed the analysis up to 3 years, depending on patient availability. This study as a fundamental and applicable one was done cross-sectionnaly. Samples were obtained randomly from the AML patients referred to the BMT center, and selection was based on the diagnostic criteria defined by clinical wards. WT1 expression in MNCs of patients was compared with 24 healthy individuals (K562 cells considered to express WT1 GENE equivalent to 106).Results: Samples for diagnosis showed significantly high levels of WT1 expression (>80%). After chemotherapy, its expression decreased (diminished about 1-2 log within induction therapy and around 3-4 log after consolidation therapy). There was a noticable correlation between the relative expression levels of WT1 and predicition of relapse (lower than gray zone versus higher than). Patients whose WT1 expression levels remained lower than the gray zone benefit from a better compete remission. On the contrary, 1-6 months prior to overt clinical relapse in 6 patients, their WT1 expression raised to levels upper than gray zone. Conclusions: This study revealed that WT1 is a useful marker for detecting minimal residual disease, assessing chemotherapy effects, and prediciting relapse in AML patients.

Cites

No record.

References

No record.

Cite

APA: Copy

HEMMATI, T., GHAFARI, H., ALI MOGHADAM, K., GHARAH BAGHIAN, A., ROSTAMI, SH., & ASHOORI, A.. (2006). ASSESSMENT OF WILMS TUMOR GENE (WT1) IN ACUTE MYELOID LEUKEMIA PATIENTS AS A NEW MARKER TO DETECT MINIMAL RESIDUAL DISEASE (MRD). THE SCIENTIFIC JOURNAL OF IRANIAN BLOOD TRANSFUSION ORGANIZATION (KHOON), 3(3), 233-241. SID. https://sid.ir/paper/78355/en

Vancouver: Copy

HEMMATI T., GHAFARI H., ALI MOGHADAM K., GHARAH BAGHIAN A., ROSTAMI SH., ASHOORI A.. ASSESSMENT OF WILMS TUMOR GENE (WT1) IN ACUTE MYELOID LEUKEMIA PATIENTS AS A NEW MARKER TO DETECT MINIMAL RESIDUAL DISEASE (MRD). THE SCIENTIFIC JOURNAL OF IRANIAN BLOOD TRANSFUSION ORGANIZATION (KHOON)[Internet]. 2006;3(3):233-241. Available from: https://sid.ir/paper/78355/en

IEEE: Copy

T. HEMMATI, H. GHAFARI, K. ALI MOGHADAM, A. GHARAH BAGHIAN, SH. ROSTAMI, and A. ASHOORI, “ASSESSMENT OF WILMS TUMOR GENE (WT1) IN ACUTE MYELOID LEUKEMIA PATIENTS AS A NEW MARKER TO DETECT MINIMAL RESIDUAL DISEASE (MRD),” THE SCIENTIFIC JOURNAL OF IRANIAN BLOOD TRANSFUSION ORGANIZATION (KHOON), vol. 3, no. 3, pp. 233–241, 2006, [Online]. Available: https://sid.ir/paper/78355/en

Related Journal Papers